Recombinant human IL-31
-
Cat.code:
rcyec-hil31
- Documents
ABOUT
Human IL-31 protein - E. coli-expressed, tag-free, carrier-free
Recombinant human IL-31 is a high-quality and biologically active cytokine, validated using proprietary IL-31 reporter cells. This member of the IL-6/gp130 family is produced in E. coli and thoroughly purified to remove endotoxins.
Recombinant human IL-31 can be used together with HEK-Blue™ IL-31 cells for the screening of inhibitory molecules, such as Nemolizumab, a therapeutic monoclonal antibody targeting the IL-31Rα subunit of the IL-31 receptor (see figures).
Key features
- Each lot is validated using HEK-Blue™ IL-31 cells
- Endotoxin ≤ 0.1 EU/µg
- 0.2 µm sterile-filtered
Applications
- Standard for IL-31 detection and quantification assays
- Screening and release assays for antibodies blocking IL-31 signaling
- Screening and release assays for engineered IL-31
Interleukin-31 (IL-31) is a cytokine that plays a role in early protective inflammatory processes, likely regulating alarmins in damaged mucosal tissues. IL-31 is strongly involved in chronic inflammation in different skin diseases, including atopic dermatitis and allergic contact dermatitis.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
Meet the MiniKines™: Collectible Cytokine Cards
Get free Minikines™ cards
with your order of recombinant cytokines.
Learn more about MiniKines™ Cards
SPECIFICATIONS
Specifications
Q6EBC2
100 μg/ml in water
Phosphate buffer saline (pH 7.4)
0.2 µm filtration
The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.
Cellular assays (tested), ELISA
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Recombinant human IL-31
-
Cat code:rcyec-hil31
-
Quantity:10 µg
1.5 ml endotoxin-free water
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
IL-31 background
The cytokine interleukin 31 (IL-31) belongs to the Type I/II cytokine receptor family, and more specifically to the IL-6/gp130 family. IL-31 signals through a heterodimeric receptor comprised of the gp130-like subunit IL-31Rα and the OSMRb (oncostatin M receptor) subunit. The binding of IL-31 to its receptor triggers activation of the JAK/STAT, Akt/PI3K, and MAPK signaling pathways [1,2]. IL-31 receptor complex is expressed in epithelial, neuronal as well as immune cells. Little is known about the physiological function of IL-31. It is mainly secreted by IL-4-activated T cells, thereby contributing to Th2-weighted inflammation [1,2]. Several reports indicate that IL-31 is implicated in disorders such as atopic dermatitis, asthma, and inflammatory bowel disease [1,2]. Of note, IL-31 appears to be a critical cytokine involved in neuro-immune communication through the mediation of inflammatory itch [1,2]. Targeting the IL-31 pathway is a promising therapeutic option for dermatologic and non-dermatologic diseases with enhanced IL-31 expression [1,2].
References:
1. Bagci I.S. and Ruzicka, T., 2018. IL-31: A new player in dermatology and beyond. J. Allergy Clin Immunol. 141(3):858-866.
2. Datsi A., et al., 2021. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 76:2982-97.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
